Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Long-Term Remission of Idiopathic Cervical Dystonia after Treatment with Botulinum Toxin

Giladi N.a · Meer J.b · Kidan H.b · Honigman S.b

Author affiliations

aDepartment of Neurology, Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, and bDepartment of Neurology, Carmel Medical Center, Haifa, Israel

Related Articles for ""

Eur Neurol 2000;44:144–146

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: October 04, 2000
Issue release date: October 2000

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE

Abstract

Botulinum toxin type A (BTX-A) treatment for cervical dystonia is traditionally considered a purely symptomatic treatment. BTX-A blocks acetyl choline exocytosis for 3–6 months and most patients require reinjection after this period. We report on 6 patients (mean age 41.6 years, range 18–69) with idiopathic cervical dystonia who were treated with BTX-A injections and became asymptomatic for 2–4 years. Four patients showed remission after the first BTX-A treatment, 1 patient after the second set of injections and 1 after the third session. Amelioration of neck dystonia was observed within 1–4 weeks after the last BTX-A treatment and all 6 patients are symptom-free, off antidystonic medications for over 2 years. The possibility that BTX-A treatment may increase the chances of development of clinical remission in patients with idiopathic cervical dystonia is discussed.

© 2000 S. Karger AG, Basel


References

  1. Jankovic J, Brin MF: Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186–1194.
  2. Greene P, Kang U, Fahn S, Brin MF, Noskowitz L, Flaster E: Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of cervical dystonia. Neurology 1990;40:1213–1218.
  3. Giladi N, Meer J, Kidan C, Greenberg E, Gross B, Honigman S: Interventional neurology: Botulinum toxin as a potent symptomatic treatment in neurology. Isr J Med Sci 1994;30:816–819.
  4. Simpson LL: Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1979;212:16.
  5. Friedman A, Fahn S: Spontaneous remission in cervical dystonia. Neurology 1986;36:398–400.
    External Resources
  6. Jahanshahi M, Marion MH, Marsden C: Natural history of adult-onset idiopathic torticollis. Arch Neurol 1990;47:548–552.
  7. Greene P, Shale H, Fahn S: Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia; in Fahn S, Marsden CP, Calne DB (eds): Advances in Neurology, Dystonia 2. New York, Raven Press, 1988, vol 50, pp 547–556.
  8. Giladi N: The non-neuromuscular effects of botulinum toxin injections. Eur J Neurol 1995;2(suppl 13):11–16.
  9. Giladi N: The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected sites. J Neurol Sci 1997;152:132–135.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: October 04, 2000
Issue release date: October 2000

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.